SCHEMBL13562147

SCHEMBL13562147

CCc1ccc2c(c1)sc1ccc3c4ccccc4ccc3c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.45
CYP2A6 P11509 2/20 0.45
HPRT1 P00492 3/20 0.40
KIF11 P52732 1/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ERBB2 P04626 1/20 0.36
FYN P06241 1/20 0.36
MAOA P21397 1/20 0.36
ACHE P22303 1/20 0.36
AHR P35869 1/20 0.36
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 3/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HIF1A Q16665 1/20 0.34
CYP1B1 Q16678 1/20 0.34
THRB P10828 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13562142 0.89 MEN1 (0.40) CYP1A2CYP2A6HPRT1ERBB2FYN
SCHEMBL13562138 0.89 CYP1A2 (0.45) CYP1A2CYP2A6HPRT1KIF11NPC1
SCHEMBL13562143 0.87 CYP1A2 (0.40) CYP1A2HPRT1TDP1HIF1ACNR2
SCHEMBL13562087 0.86 CYP1A2 (0.49) CYP1A2CYP2A6KIF11NPC1RAB9A
SCHEMBL13562146 0.85 CYP1A2 (0.39) CYP1A2HPRT1NPC1RAB9ASMN1; SMN2
SCHEMBL14325124 0.84 CYP1A2 (0.49) CYP1A2CYP2A6KIF11NPC1RAB9A
SCHEMBL13562145 0.84 HPRT1 (0.44) CYP1A2CYP2A6HPRT1NPC1RAB9A
SCHEMBL13562202 0.82 CYP2A6 (0.47) CYP1A2CYP2A6HPRT1KIF11NPC1
SCHEMBL13562140 0.78 MEN1 (0.35) CYP1A2CYP2A6NPC1RAB9ASMN1; SMN2
SCHEMBL7773085 0.78 CYP1A2 (0.67) CYP1A2CYP2A6HPRT1KIF11ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8766243-B2 Heterocycle-containing asymmetric aromatic compound, compound for organic thin film transistor, and organic thin film transistor using the same IDEMITSU KOSAN CO., LTD. (JP) 2014-07-01 US disclosed
US-8766243-B2 Heterocycle-containing asymmetric aromatic compound, compound for organic thin film transistor, and organic thin film transistor using the same IDEMITSU KOSAN CO., LTD. (JP) 2014-07-01 US disclosed
US-20120273768-A1 HETEROCYCLE-CONTAINING ASYMMETRIC AROMATIC COMPOUND, COMPOUND FOR ORGANIC THIN FILM TRANSISTOR, AND ORGANIC THIN FILM TRANSISTOR USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-11-01 US disclosed
US-20120273768-A1 HETEROCYCLE-CONTAINING ASYMMETRIC AROMATIC COMPOUND, COMPOUND FOR ORGANIC THIN FILM TRANSISTOR, AND ORGANIC THIN FILM TRANSISTOR USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120273768-A1 HETEROCYCLE-CONTAINING ASYMMETRIC AROMATIC COMPOUND, COMPOUND FOR ORGANIC THIN FILM TRANSISTOR, AND ORGANIC THIN FILM TRANSISTOR USING THE SAME TCF4, TPR, H1-4 CYP1A2 160/4885CYP2A6 933/4885HPRT1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.